Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients

NCT01885013 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

OTHER

Sponsor class

Conditions

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Interventions

DRUG: Metformin + Myocet + Cyclophosphamide
DRUG: Myocet + Cyclophosphamide

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS